Attached files
| file | filename |
|---|---|
| EX-99 - PRESS RELEASE - K-V Pharmaceutical Co | dex99.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): June 11, 2010
K-V PHARMACEUTICAL COMPANY
(Exact name of registrant as specified in its charter)
Commission File Number 1-9601
| Delaware | 1-9601 | 43-0618919 | ||
| (State or other jurisdiction | (Commission | (I.R.S. Employer | ||
| of incorporation) | File Number) | Identification No.) |
| One Corporate Woods Drive Bridgeton, MO | 63044 | |
| (Address of principal executive offices) | (Zip Code) |
(314) 645-6600
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act. |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
Item 8.01 Other Events.
On June 11, 2010, K-V Pharmaceutical Company (the “Registrant”) issued a press release announcing the results of the election for directors conducted its Annual Meeting of Shareholders on June 10, 2010 for the fiscal year ended March 31, 2009. The press release also announced a restructuring of senior executive management of the Registrant.
A copy of the press release is attached hereto as Exhibit 99. The Registrant has posted this Form 8-K on its Internet website at www.kvpharmaceutical.com. References to the Registrant’s website address are included in this Form 8-K and the press release only as inactive textual references and the Registrant does not intend them to be active links to its website. Information contained on the Registrant’s website does not constitute part of this Form 8-K or the press release.
Item 9.01 Financial Statements and Exhibits.
(d) The following exhibit is filed as part of this report:
| Exhibit Number |
Description | |
| 99 |
Press Release dated June 11, 2010, issued by K-V Pharmaceutical Company. |
* * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 14, 2010
K-V PHARMACEUTICAL COMPANY
By: /s/ Gregory J. Divis, Jr.
Name: Gregory J. Divis, Jr.
Title: Interim President and Chief Executive Officer